Welcome to our dedicated page for Medtronic SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medtronic plc filings document material events, capital structure, registered securities, governance matters, and operating and financial disclosures for a medical-device company organized in Ireland. The 8-K record identifies MDT ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, alongside current reports used for company events and financial-result communications.
The filing record also includes exchange and registration status for debt securities, including a Form 25 notice tied to removal from listing and registration of a guarantor class of senior notes. These disclosures frame Medtronic's public-company obligations around equity, debt instruments, material agreements, and regulatory or clinical developments.
Medtronic plc director Elizabeth G. Nabel reported routine equity compensation activity in company ordinary shares. She received an award of 2,111 restricted stock units, which vest on the one-year anniversary of the award date. The filing also reports 207 shares withheld to cover taxes upon the vesting of previously granted restricted stock units, a non‑market, tax-withholding disposition rather than an open-market sale. Following these transactions, she directly holds 19,584 ordinary shares, including 65 shares acquired through dividend reinvestment since her last report.
Medtronic plc director Kevin E. Lofton reported routine equity compensation activity involving Ordinary Shares. On April 27, 2026, he acquired 2,111 shares at $0.00 per share as a grant of restricted stock units that vest on the one-year anniversary of the award date.
On April 28, 2026, 207 shares were withheld at $81.90 per share to cover taxes upon vesting of previously reported restricted stock units, a tax-withholding disposition rather than an open-market sale. Following these transactions, he directly holds 10,140 Ordinary Shares, which include 65 shares acquired through dividend reinvestment since his last report.
Medtronic plc director Lewis Gregory P reported routine equity compensation activity. On April 27, 2026, he acquired 2,111 Ordinary Shares through a grant of restricted stock units that vest on the one-year anniversary of the award date. The position also now includes 65 shares acquired through dividend reinvestment since his last report. On April 28, 2026, 207 shares were withheld at $81.90 per share to cover taxes upon the vesting of previously granted restricted stock units, a non-market disposition. After these transactions, he directly holds 5,754 Ordinary Shares.
Lee Joon Sup reported acquisition or exercise transactions in this Form 4 filing.
Medtronic plc reported that director Lee Joon Sup received an equity award of 1,803 ordinary shares in the form of restricted stock units. These units were granted at no cash cost and will vest on the one-year anniversary of the award date. Following this grant, Lee directly holds 1,803 ordinary shares.
Jellison William R reported acquisition or exercise transactions in this Form 4 filing.
Medtronic plc director William R. Jellison received an equity award of 1,444 ordinary shares at a price of $0.00 per share. This reflects a grant or award, not an open-market purchase. Following the award, he directly owns 6,444 ordinary shares.
According to the footnote, the grant represents restricted stock units that vest on the one-year anniversary of the award date, tying the compensation to continued service over that period.
Medtronic plc director Randall J. Hogan reported routine equity compensation activity. He received an award of 2,111 ordinary shares in the form of restricted stock units that vest on the one-year anniversary of the award date. In a related move, 207 shares were withheld to cover tax obligations when previously granted restricted stock units vested, rather than being sold on the open market. Following these transactions, he directly holds 48,998 ordinary shares, which includes 65 shares acquired through dividend reinvestment since his last report.
Groetelaars John P reported acquisition or exercise transactions in this Form 4 filing.
Medtronic plc director John P. Groetelaars received a stock award rather than buying shares on the market. He was granted 1,444 ordinary shares on a Form 4 report, at a stated price of $0.00 per share, as compensation.
The award represents restricted stock units that vest on the one-year anniversary of the grant date, so he must remain eligible through that period to receive the shares. Following this grant, his directly held position reported in this filing is 1,444 ordinary shares, reflecting a small, routine equity award for a board member.
Medtronic plc director Lidia Fonseca reported routine equity compensation activity. She received an award of 2,111 ordinary shares in the form of restricted stock units that vest on the one-year anniversary of the award date.
Upon vesting of previously granted restricted stock units, 207 shares were withheld to cover taxes at a price of $81.90 per share. After these transactions, she directly owns 7,644 Medtronic ordinary shares, which includes 65 shares acquired through dividend reinvestment since her last report.
Medtronic plc director Scott C. Donnelly reported routine equity compensation activity. He received a grant of 2,111 ordinary shares in the form of restricted stock units, which vest on the one-year anniversary of the award date. When previously granted units vested, 207 shares were withheld at $81.90 per share to cover related tax obligations, rather than being sold on the market. Following these transactions, he directly holds 23,679 Medtronic ordinary shares, including 145 shares acquired through dividend reinvestment since his last report.
Medtronic plc director Craig Arnold reported routine equity compensation activity involving the company’s ordinary shares. He received an award of 2,111 restricted stock units that vest on the one-year anniversary of the award date, increasing his direct holdings.
When previously granted restricted stock units vested, 207 shares were withheld to cover taxes, a non-market disposition used for tax payment rather than an open-market sale. Following these transactions, he directly owned 42,185 shares, which includes 65 shares acquired through dividend reinvestment since his last report.